CVS stock forecast, quote, news & analysis

Key Takeaways

• CVS Health delivered Q4 2025 revenue of $105.7 billion, up 8.2% year-over-year, beating estimates despite shares sliding 3.7% on reaffirmed 2026 guidance.
• Adjusted EPS hit $1.09 for the quarter, surpassing expectations, with full-year 2025 adjusted EPS at $6.75.
• 2026 outlook steady at adjusted EPS of $7.00-$7.20 and revenue of at least $400 billion, amid Medicare Advantage cost pressures.
• Pharmacy & Consumer Wellness segment grew 12.4% in Q4, driving overall momentum in the turnaround plan.
• Analysts maintain a consensus Buy rating with an average price target around $95, signaling upside potential.
• Health Care Benefits faces elevated medical costs, but PBM and retail pharmacy strengths provide balance.

Current Market Snapshot

CVS Health stock has navigated volatility in recent trading sessions, reflecting broader pressures in the health insurance sector alongside resilient pharmacy operations. Shares have traded within a 52-week range marked by lows near $58 and highs above $85, with recent weeks showing gains tempered by post-earnings caution. The company's integrated model—spanning retail pharmacy, benefits management, and health services—continues to deliver revenue growth, even as medical cost trends challenge margins in Medicare Advantage. Investor sentiment balances turnaround progress against regulatory and reimbursement uncertainties, positioning CVS as a watchlist staple for those eyeing healthcare consolidation trends.

Trending AI Robots

Tickeron’s Trending AI Robots page showcases a curated selection of the platform's top-performing AI Trading Bots, drawn from hundreds of sophisticated algorithms that trade thousands of tickers across stocks, ETFs, and crypto. These bots employ diverse strategies—including trend-following, countertrend, high-frequency signals on 5-, 15-, and 60-minute timeframes, and multi-agent systems—tailored to current market conditions like volatility in healthcare or tech sectors. Standouts have delivered impressive stats, such as annualized returns exceeding 135% in healthcare-focused bots, up to 338% in high-frequency agents, win rates above 70%, and perfect 100% profitable trades in select 30-day periods. Only the most suitable, battle-tested performers earn a spot in this dynamic ranking, helping traders identify opportunities with data-driven precision. Explore Trending AI Robots to see real-time leaders and backtested results for your portfolio.

Recent Developments Driving CVS Price Action

CVS Health's stock has experienced choppy price action in recent weeks, largely tied to quarterly results and sector headwinds. The standout event was the February 10 release of Q4 2025 earnings, which showcased robust top-line growth but triggered a 3.7% share decline amid tempered guidance expectations. Total revenue reached $105.7 billion, an 8.2% increase from the prior year and above the $103.6 billion consensus, fueled by strength across all segments. Pharmacy & Consumer Wellness led with 12.4% revenue growth to $37.7 billion, driven by a 6.3% rise in prescriptions filled to 473.8 million. Health Services, including PBM Caremark, posted $51.2 billion in revenue (up 9%), while Health Care Benefits grew 10.1% to $36.3 billion despite a Q4 adjusted operating loss of $676 million from elevated medical costs.

Adjusted EPS of $1.09 beat the $1.00 estimate, though down slightly from $1.19 year-over-year, with full-year 2025 adjusted EPS improving to $6.75. However, the market reaction hinged on reaffirmed 2026 guidance: adjusted EPS of $7.00-$7.20 (midpoint below some $7.18 analyst hopes) and revenue of at least $400 billion, roughly flat from 2025's record $402.1 billion. Cash flow guidance was trimmed to at least $9 billion from $10 billion, citing timing shifts, which amplified concerns over Medicare Advantage reimbursement and medical loss ratios hovering near 92-95%.

Earlier pressures stemmed from January's CMS proposal for modest 2027 Medicare Advantage rate hikes (0.09%), far below 4-6% expectations, sparking a sector-wide selloff and contributing to CVS's dip toward $73 intraday post-earnings. Regulatory scrutiny on PBMs intensified, with CVS defending its Caremark model amid branded drug price hikes adding $25 billion in system costs. Bank of America adjusted estimates post-earnings but held a $95 target, while firms like Argus and Evercore maintained Buy ratings, citing pharmacy momentum and Aetna margin recovery. These developments linked directly to sentiment shifts: beats buoyed intraday recoveries, but conservative outlook and MA woes fueled downside, with shares rebounding modestly to around $78 amid broader healthcare turmoil.

2026 Outlook and Key Factors to Monitor

As CVS Health advances its turnaround, 2026 will hinge on executing margin recovery in Health Care Benefits while leveraging pharmacy and PBM strengths. Guidance points to adjusted EPS growth to $7.00-$7.20 and sustained revenue above $400 billion, supported by Aetna's medical cost stabilization and Caremark's transparency tools like TrueCost amid PBM reforms. Investors should track CMS final 2027 Medicare Advantage rates in April, Star Ratings impacts on bonuses, and medical loss ratio trends, as elevated costs could pressure profitability.

Opportunities lie in Pharmacy & Consumer Wellness expansion, with rising prescription volumes and biosimilar adoption, plus value-based care via Oak Street Health and Signify. Risks include antitrust probes, rebate legislation, and branded drug inflation outpacing reimbursements. Competitive positioning in integrated care, alongside macroeconomic factors like inflation and interest rates, will shape cost structures. Balanced growth across segments positions CVS to navigate these dynamics, with cumulative 2025-2026 cash flow up $1.5 billion versus prior views.